Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Adaptive Biotechnologies has a “Moderate Buy” consensus rating from seven analysts: five buys, one hold and one sell. The average 12-month price target is $24.42, below the stock’s reported $25.99 opening price.
• Insiders sold 2.06 million shares worth approximately $46.7 million over the past three months, including CEO Chad Robins’ sale of 278,676 shares. Insiders retain a 5.70% ownership stake.
• The company’s latest quarterly revenue rose 21.5% year over year to $71.55 million, exceeding estimates, but its adjusted loss of $0.25 per share was wider than the expected $0.13 loss.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $24.4167.

A number of equities research analysts have recently weighed in on ADPT shares. BTIG Research boosted their price objective on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. Morgan Stanley lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 30th. Weiss Ratings restated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. JPMorgan Chase & Co. reduced their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 6th. Finally, TD Cowen lifted their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a "buy" rating in a report on Thursday, July 30th.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Susan Bobulsky sold 3,000 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the sale, the insider owned 396,989 shares in the company, valued at approximately $9,924,725. The trade was a 0.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad M. Robins sold 278,676 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $24.48, for a total value of $6,821,988.48. Following the completion of the sale, the chief executive officer owned 2,180,518 shares of the company's stock, valued at $53,379,080.64. The trade was a 11.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 2,062,325 shares of company stock worth $46,659,069 over the last three months. Corporate insiders own 5.70% of the company's stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

Institutional investors have recently added to or reduced their stakes in the company. Nykredit A S purchased a new position in shares of Adaptive Biotechnologies in the second quarter valued at about $31,000. Allworth Financial LP bought a new position in shares of Adaptive Biotechnologies during the second quarter valued at about $35,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Adaptive Biotechnologies during the fourth quarter valued at about $28,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after purchasing an additional 1,565 shares during the period. Finally, Assetmark Inc. boosted its holdings in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company's stock worth $49,000 after purchasing an additional 2,708 shares during the period. Hedge funds and other institutional investors own 99.17% of the company's stock.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ ADPT opened at $25.99 on Friday. The stock's 50-day moving average is $22.06 and its 200 day moving average is $17.35. The stock has a market cap of $4.15 billion, a price-to-earnings ratio of -63.39 and a beta of 2.08. Adaptive Biotechnologies has a 1-year low of $12.00 and a 1-year high of $26.16. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm had revenue of $71.55 million during the quarter, compared to analysts' expectations of $65.44 million. During the same period in the prior year, the company earned ($0.17) EPS. The firm's quarterly revenue was up 21.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Adaptive Biotechnologies will post -0.4 EPS for the current fiscal year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source